Autophagy and mitochondrial deficits are characteristics of early phase of Alzheimer's
disease (AD). Sodium-glucose cotransporter-2 inhibitors have been nominated as a …

Alzheimer's disease (AD) is the most common form of neurodegenerative disorders
worldwide. Its pathologic features include massive neuroinflammation with abnormal …

Alzheimer's disease (AD) is a progressive neurological illness characterized by memory loss
and cognitive deterioration. Dapagliflozin was suggested to attenuate the memory …

Anxiety is a neuropsychiatric disturbance that is commonly manifested in various dementia
forms involving Alzheimer's disease (AD). The mechanisms underlying AD-associated …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has featured
marked anti-inflammatory effects in murine models of myocardial infarction, renal injury, and …

Cognitive impairment is increasingly recognized as an important comorbidity of diabetes
progression; however, the underlying molecular mechanism is unclear. Dapagliflozin, an …

Aims Huntington's disease is a rare neurodegenerative disorder which is associated with
defected glucose metabolism with consequent behavioral disturbance including memory …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged
as a promising neuroprotective agent in murine models of epilepsy and obesity-induced …

Cognitive decline and Alzheimer-like neuropathology are common manifestations of
cadmium toxicity. Thanks to its antioxidant/anti-apoptotic features, dapagliflozin has …

Excessive accumulation of advanced glycation end products (AGEs) contributes to
autophagy interruption on podocytes and insufficient autophagy on podocytes is …